MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.euroneuro.2009.10.005

Медицинская библиотека · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2009

Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder.

Tauscher Johannes, Kielbasa William, Iyengar Smriti, Vandenhende Francois, Peng Xiaomei, Mozley David, Gehlert Donald R, Marek Gerard

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

The neurokinin-1 (NK-1) antagonist LY686017 showed activity in preclinical anxiety models. The clinical development of LY686017 included a PET study and a proof-of-concept in social anxiety disorder (SAD). [(11)C]GR205171 was used healthy volunteers receiving 1-100mg/d LY686017 for 28 days to determine brain receptor occupancy (RO). The mean NK-1 RO increased ranged from 25% with 1mg to 93% with 100mg. Subsequently, a 12-week randomized clinical trial tested LY686017 vs. paroxetine, or placebo in SAD. Pharmacokinetic (PK)/RO modeling based on the PET results predicted that once daily dosing of >30mg LY686017 led to sustained trough RO of over 80%. 189 outpatients(1) suffering from SAD were randomly assigned to 12-weeks treatment with 50mg/d LY686017 (N=77), placebo (N=74), or 20mg/d paroxetine (N=38). There was no significant difference between LY686017 and placebo as measured with the Liebowitz Social Anxiety scale (LSAS). The active comparator paroxetine showed positive trends on primary and secondary measures. The plasma concentrations were above the level expected to produce maximal brain NK-1 RO based on the PK/RO relationship obtained in the human PET investigation. Thus, further evaluation of LY686017 for the treatment of SAD does not seem warranted.

Для цитирования: Tauscher Johannes, Kielbasa William, Iyengar Smriti, Vandenhende Francois, Peng Xiaomei, Mozley David, Gehlert Donald R, Marek Gerard. Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder.. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2009. DOI: 10.1016/j.euroneuro.2009.10.005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.